Omega-3 polyunsaturated fatty acids in the prevention of relapse in patients with stable bipolar disorder: A 6-month pilot randomized controlled trial

Psychiatry Res. 2024 Jan:331:115633. doi: 10.1016/j.psychres.2023.115633. Epub 2023 Nov 26.

Abstract

This study investigated the efficacy and safety of omega-3 polyunsaturated fatty acids (n-3 PUFAs) in relapse prevention of bipolar disorder (BD), addressing the shortcomings of current medications. Thirty-one stable BD patients were randomized to receive n-3 PUFAs or placebo for 6 months and intergroup differences in the incidence of the recurrence of bipolar depression were assessed. Differences in depression severity, manic symptoms, and routine biochemical parameters were also assessed. Interestingly, n-3 PUFAs demonstrated a favorable preventive effect on bipolar depression recurrence (p=0.005; Log-Rank) and reduced depression severity compared to placebo, and were well-tolerated, suggesting their potential as a safe prophylactic therapy for BD.

Keywords: Bipolar depression; Mania; Omega-3 polyunsaturated fatty acids.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Bipolar Disorder* / diagnosis
  • Bipolar Disorder* / drug therapy
  • Fatty Acids, Omega-3* / pharmacology
  • Fatty Acids, Omega-3* / therapeutic use
  • Humans
  • Pilot Projects
  • Recurrence

Substances

  • Fatty Acids, Omega-3